Impact of the COVID-19 pandemic on hematopoietic stem cell transplant programmes in Singapore.

Timothy Lam Jia Rong, Gayathri Basker, Chan Yong Hoe, Than Hein, Li Mei Michelle Poon, Goh Yeow Tee
{"title":"Impact of the COVID-19 pandemic on hematopoietic stem cell transplant programmes in Singapore.","authors":"Timothy Lam Jia Rong, Gayathri Basker, Chan Yong Hoe, Than Hein, Li Mei Michelle Poon, Goh Yeow Tee","doi":"10.31547/bct-2023-019","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hematopoietic stem cell transplantation (HSCT) has been performed in Singapore since 1985. Currently, more than 100 transplants are performed annually across the public and private sectors. In 2020, the COVID-19 pandemic resulted in unprecedented disruptions to global healthcare systems, and Singapore was no exception. In particular, the field of HSCT faced additional, unique challenges aside from those borne by the healthcare system at large, and appropriate measures were necessary to ensure that HSCT remained available to patients who needed it.</p><p><strong>Methods: </strong>The expert opinions of six hematologists from various institutions across Singapore were gathered through individual interviews and summarized. This was supplemented by a literature review on bone marrow donation and HSCT in Singapore.</p><p><strong>Main findings and conclusion: </strong>In Singapore, the COVID-19 pandemic has had significant implications for HSCT, ranging from the implementation of additional infection control measures in hospitals to an accelerated rise in haploidentical transplants. Further research is required to better understand and quantify these impacts, improve existing processes, and investigate the effects of COVID-19 and its treatment modalities on patients with HSCT.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"6 4","pages":"139-144"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10749730/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood cell therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31547/bct-2023-019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hematopoietic stem cell transplantation (HSCT) has been performed in Singapore since 1985. Currently, more than 100 transplants are performed annually across the public and private sectors. In 2020, the COVID-19 pandemic resulted in unprecedented disruptions to global healthcare systems, and Singapore was no exception. In particular, the field of HSCT faced additional, unique challenges aside from those borne by the healthcare system at large, and appropriate measures were necessary to ensure that HSCT remained available to patients who needed it.

Methods: The expert opinions of six hematologists from various institutions across Singapore were gathered through individual interviews and summarized. This was supplemented by a literature review on bone marrow donation and HSCT in Singapore.

Main findings and conclusion: In Singapore, the COVID-19 pandemic has had significant implications for HSCT, ranging from the implementation of additional infection control measures in hospitals to an accelerated rise in haploidentical transplants. Further research is required to better understand and quantify these impacts, improve existing processes, and investigate the effects of COVID-19 and its treatment modalities on patients with HSCT.

Abstract Image

Abstract Image

COVID-19 大流行对新加坡造血干细胞移植计划的影响。
背景:新加坡自 1985 年起开始进行造血干细胞移植(HSCT)。目前,公共和私营部门每年进行 100 多例移植手术。2020 年,COVID-19 大流行给全球医疗系统带来了前所未有的混乱,新加坡也不例外。尤其是造血干细胞移植领域,除了整个医疗系统面临的挑战外,还面临着更多独特的挑战,因此有必要采取适当措施,确保有需要的患者能够继续接受造血干细胞移植:通过个别访谈收集了来自新加坡不同机构的六位血液学专家的意见,并进行了总结。主要研究结果和结论:在新加坡,COVID-19 大流行对造血干细胞移植产生了重大影响,从医院实施额外的感染控制措施到单倍体移植的加速增加,不一而足。为了更好地了解和量化这些影响、改进现有流程并调查 COVID-19 及其治疗模式对造血干细胞移植患者的影响,需要开展进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信